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Abstract Limited data are available about the ultrasound
(US)-detected inflammatory features in patients with suspi-
cion of inflammatory arthritis (S-IA) vs. established rheuma-
toid arthritis (RA). Our study aimed to assess if the presence of
power Doppler (PD) can be predicted by a combination of
clinical, laboratory and US parameters. We conducted a real-
life, retrospective cohort study comparing clinical, laboratory
and US parameters of 108 patients with established RA and 93
patients with S-IA. We propose a PD signal prediction model
based on a beta-binomial distribution for PD variable using a
mix of outcome measures. Patients with RA in clinical remis-
sion had significantly more active inflammation and erosions
on US when compared with patients with S-IA with similar
disease scores (p = 0.03 and p = 0.01, respectively); however,
RA patients with different disease activity score (DAS-28)
scores had similar PD scores (p = 0.058). The PD scores did
not correlate with erosions (p = 0.38) or DAS-28 scores
(p = 0.28) in RA patients, but they correlatedwith high disease
activity in S-IA patients (p = 0.048). Subclinical inflammation
is more common in patients with RA in clinical remission or
with low disease activity than in patients with S-IA; therefore,
US was more useful in assessing for true remission in RA
rather than diagnosing IA in patients with low disease activity
scores. This is the first study to propose a PD prediction model
integrating several outcome measures in the two different
groups of patients. Further research into validating this model
can minimise the risk of underdiagnosing subclinical
inflammation.
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Introduction
Ultrasound (US) assessment of small joints is routinely used
for the diagnosis of peripheral inflammatory arthritis (IA) and
helps guiding therapeutic decisions in patients with
established rheumatoid arthritis (RA) [1]. The access to mus-
culoskeletal US services varies among hospitals and rheuma-
tology services. The usefulness of the US examination for the
diagnosis and management of RA depends on the level of
expertise of examiners and quality of the US machines [2].
Even if a considerable proportion of patients with established
RA continue to have subclinical inflammation, despite evi-
dence of clinical remission, it is not cost-effective to screen
them all. Extensive US examination of peripheral joints in RA
had a good predictive value for disease outcome, as
established by an 18-month longitudinal study [3]. As the
US examination of multiple joints can be time consuming,
several US scoring systems have been developed, aiming to
assess a smaller number of joints without compromising on
the quality of data collected [4].
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There are no guidelines to help us decide which RA pa-
tients should have an US scan of their joints or how often,
despite the constant effort to generate recommendations re-
garding the use of imaging techniques in the management of
patients with RA [5]. There is no straightforward indicator of
the risk of continuing with active joint inflammation, despite
the use of several US prediction factors for disease progres-
sion and damage [6–8].
The OMERACT (Outcome Measures in RA Clinical
Trials) initiative defined the US abnormalities characteristic
for RA as synovial hypertrophy (SH), with or without power
Doppler (PD) signal, tenosynovitis and erosions [4, 9].
The available US scoring systems use different quantitative
or semiquantitative measures (such as grades of SH or PD) or
a binary scoring system (such as presence/absence of ero-
sions) to express US findings [4]. The principal aim of the
international and European US expert groups is to develop a
standardised US scoring system which will capture the pa-
tient’s global disease activity and which can be employed to
guide therapeutic decisions [10].
As several outcome measures are required to establish if
patients with RA have active disease or not, we identified the
need to integrate clinical and laboratory parameters in a pre-
diction model that could improve the quality of care we pro-
vide to our patients, by enabling the identification of those at
risk of having positive PD signal in their joints. In an ideal
situation, patients with a previous diagnosis of RA or with the
suspicion of having developed IA are offered an US exami-
nation of their joints to increase the chance of correct diagno-
sis and optimise disease control. In reality, because of limited
resources, patients are referred to US clinics in a selective
manner, based on their clinician expertise and need, and avail-
ability of US resources. However, it is widely recognised that
subtle joint inflammation is often missed by the clinical ex-
amination [11]. It was proposed that RA treatment should
target the control of sub-clinical inflammation (as assessed
by US or MRI), instead of being exclusively guided by clin-
ical examination and laboratorymeasures [12], and that remis-
sion criteria for patients with RA should also include joint US
examination [13, 14].
The rationale of our research project was to generate useful
information for clinicians that can be easily applied in real life
and can help identify patients at risk of having active inflam-
mation in their joints. Our statistical modelling framework is
based on data routinely collected from a heterogeneous RA
population.
The aim of our study was to build a statistical model to
assess the influence of several outcome measures on the pres-
ence of PD signal. The selected outcomes were as follows: the
number of tender joints (TJC) and swollen joints (SJC) out of
28, global health state as assessed using a visual analogue
scale (GVAS), high-sensitivity C-reactive protein (hsCRP),
erythrocyte sedimentation rate (ESR), presence of rheumatoid
factor (RF) and anti-citrullinated cyclic peptides antibodies
(ACPA) and anti-nuclear antibodies (ANA), disease duration
and medication. In order to generate this prediction model, we
collected similar data from the two groups of patients (with
suspicion of inflammatory arthritis (S-IA) and RA) and
assessed the influence of every parameter on the patients’ risk
of having active PD in their joints.
Methods
Subjects
We conducted a real-life, retrospective cohort study of patients
seen to our US outpatient clinics in the order of their referral,
between May 2013 and September 2013. We used an
established protocol of US examination of hands comprising
flexor tendons and 22 joint assessments (dorsal longitudinal
and transverse views), which is the standard of practice for our
US clinics. All the patients were referred to this clinic for
inflammatory symptoms in their hands, and their clinical ex-
amination was equivocal. No inclusion or exclusion criteria
were applied for the selection of patients, to ensure the general
applicability of the prediction model we propose. Patients on
oral steroids or NSAIDs, or who had steroid injections less
than 4 weeks before the US scan, were excluded from the final
analysis. We report data on the two largest groups, the patients
with established RA and patients with S-IA, using descriptive
statistics (SPSS, version 22). We also stratified patients based
on their disease activity assessed using the disease activity
score assessing 28 joints (DAS-28). Patient groups with dif-
ferent DAS scores were compared using ANOVA/chi-squared
test depending on the variables analysed (p < 0.05 was con-
sidered significant). We also performed a cluster analysis of
patients with similar DAS-28 scores using the aforementioned
outcome measures.
Ultrasound examination
US examination was performed using a Logiq S8 USmachine
(GE Medical Systems Ultrasound and Primary Care
Diagnostics, Wauwatosa, WI, USA), equipped with a multi-
frequency linear matrix array transducer (6–15 MHz). B-
mode and PD machine setting are optimised and standardised
for all our patients’ US examinations. The settings used were
as follows: B-mode frequency 11–15 MHz and Doppler fre-
quency 7.5–15 depending on the depth of the anatomical area,
Doppler gain around 18 dB, low wall filters and pulse repeti-
tion frequency 800 Hz. Because of the small number of joints
with PD signal (only patients with equivocal clinical exami-
nation were referred for anUS examination of their hands), we
did not report separately the grades of PD signal.
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Statistical analysis for the prediction model
We proposed a regression model to assess the contribution of
every outcome measure to the risk of having active joint in-
flammation as well as predict PD signal. We excluded patients
with PD signal present in more than 10/22 joints to ensure
homogeneity in the data. We conducted a real-life study in-
cluding 276 patients referred for the suspicion of active joint
inflammation (new referrals for S-IA, RA patients and patients
with other inflammatory rheumatic conditions). We assessed
22 hand joints in every patient, irrespective of their hand
symptoms, using the OMERACT scoring system for US ex-
amination. The proposed regression model was based on a
beta-binomial distribution (with the response ranging from 0
to 10) for the PD score variable and a mix of main interaction
effects for the outcome measures stated earlier. Negative in-
teraction effects show that the respective outcome is associat-
ed with a lower number of joints with PD signal.
Results
We collected data from 276 consecutive patients referred to
our rheumatologist-led US clinic to have a scan of their hand
joints aiming to answer the clinician question about the pres-
ence of active inflammation in their joints. There were 108
patients with established RA, 93 were referred for the clinical
suspicion of IA, 29 were previously diagnosed with psoriatic
arthritis (PsA) and 46 patients had other diagnoses, including
crystal arthropathies, sarcoidosis, osteoarthritis and chronic
pain. We analysed in parallel the characteristics of the two
main groups of patients: the group of established RA (n =
108) and the group of patients referred with S-IA (n = 93)
(Table 1). The assessment of the follow-up clinical letters of
S-IA patients revealed that 50.5 % (n = 47) were ultimately
diagnosed with a form of IA, out of which 76.5 % (n = 36)
were diagnosed with RA, 12.7 % (n = 6) with undifferentiated
IA and 10.6 % (n = 5) with psoriatic arthritis. The rest of the
patients initially referred with the suspicion of IA (49.4 %)
were subsequently diagnosed with non-specific arthralgia,
chronic pain or hand osteoarthritis.
The patients in the RA group were treated with methotrex-
ate (MTX) alone or in combination with other synthetic
disease-modifying anti-rheumatic drugs (DMARDs) in
79.6 % (86/108), SSZ alone or in combination in 48.1 %
(52/108) and HCQ alone or in combination in 58.3 % (58/
108). In terms of biologic treatments, 24.07 % (26/108) were
on etanercept, 12 % (13/108) on adalimumab, 0.018 % on
certolizumab (2/108), 0.09 % on rituximab (10/108) and
0.055 % on tocilizumab (6/108). Out of 108 patients with
established RA, 89 patients (82.4 %) were on combination
therapy. The RA patients were on stable conventional and
biologic DMARD medication for at least 1 month prior to
the scan. A minority of patients (21/108 in the RA group
and 9/93 in the S-IA group) were treated with additional
NSAIDs, and one S-IA had oral steroids (Table 1). These
patients were excluded from the further analysis that stratified
them based on their disease activity.
The comparison between the RA and S-IA groups with
regard of the demographic, clinical, laboratory and US fea-
tures is summarised in Table 1. The median number of joints
with PD activity was significantly higher in RA patients (0,
interquartile range (IQR) = 2.25 vs. 0, IQR = 1, p = 0.03), as
was the number of joints with erosions (p = 0.004) and the
number of joints with joint effusions (1.5 vs. 0, p = 0.013).
However, the percentage of patients having at least one joint
with active inflammation, as assessed by the presence of PD
signal, was not significantly different between the two groups
(52/93, 55.9 % vs. 45/108, 41.6 %, p = 0.56). Tendon abnor-
malities (such as effusion and tendon sheet thickening) were
more frequently observed in patients with RA vs. S-IA (14/
108 vs. 3/93, p = 0.042). The number of clinically assessed
swollen joints correlated poorly with the US-detected inflam-
mation (as assessed by PD signal) in both groups of RA and S-
IA patients (r = 0.27, p = 0.54 and r = 0.39, p = 0.72,
respectively).
The majority of patients with S-IA and positive PD signal
in at least one joint (n = 52) were subsequently diagnosed with
a type of inflammatory arthritis (47/52, 90.3 %), out of which,
36 patients were diagnosed with RA (69.2 %). In five cases,
the presence of PD was associated with osteophytes and they
have been diagnosed with inflammatory OA. Out of 25.8% of
patients with S-IAwho had positive RF at the time of the US
scan (n = 24/93), 23 patients were subsequently diagnosed
with RA (23/36, 63.3 %); similarly, a proportion of ACPA-
positive S-IA patients were ulterior diagnosed with RA (18/
36, 50 %).
Further analysis compared RA patients stratified based on
the DAS-28 activity scores (Table 2), and similarly, Table 3
comprises data on the S-IA group (Table 3). As mentioned
earlier, the patients on oral steroids and NSAIDs were exclud-
ed from this analysis, which reported data on 87 RA and 82 S-
IA patients. As expected, the RA patients stratified based on
their DAS-28 scores had statistically different ESR, TJC, SJC,
GVAS and pain scores; however, they had similar US param-
eters assessing for active and chronic inflammatory changes
(Table 2). In contrast, the analysis of patients with S-IA re-
vealed that DAS-28 score stratification identified patients with
different PD and SH grade 3 scores, CRP and ESR levels, as
well as patients with different TJC, SJC, GVAS and pain
scores (Table 3). In addition, the S-IA groups with low, mod-
erate and active diseases had a larger proportion of patients
with true active inflammation (based on PD signal) than the
group classified as being in clinical remission (p = 0.01)
(Table 3). The comparison between the patient groups with a
similar disease activity revealed that patients with RA and
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moderate and high disease activities (DAS-28 = 3.2–5.1 and
>5.1, respectively) were significantly different from S-IA pa-
tients with similar DAS-28 scores, as far as the disease dura-
tion, ACPA positivity and number of joints with erosions were
concerned (Table 4). RA patients in remission (DAS-28 < 2.6)
had significantly higher TJC, number of joints with active
inflammation and erosions, and higher number of patients
with subclinical inflammation than the S-IA patients classified
as being in clinical remission (Table 4). We also assessed for
correlations between PD signal and erosions in RA patients in
all the disease activity groups, and there were no positive
correlations (p = 0.06, p = 0.26, p = 0.49, p = 0.12 for the dif-
ferent DAS-28 score groups, and p = 0.38 for the whole RA
group, respectively). Out of all clinical outcomes, only SJC
correlatedwith the PD score and only in patients with RA (p =
0.03). The presence of erosions also correlated with the pa-
tient’s age and disease duration (p = 0.04 and p = 0.03,
respectively).
Most importantly, the DAS-28 scores did not correlate sig-
nificantly with the PD scores in the RA patients (p = 0.25, p =
0.87, p = 0.13, p = 0.22, respectively, for the remission, low,
moderate and active diseases, respectively). However, in the
Table 1 Comparison between patients with S-IA and established RA
Disease S-IA (n = 93) RA (n = 108) p value
Mean age ± SD 50.69 ± 15.7 55.9 ± 15.2 0.04
Sex (%) 87.1 % F (n = 81) 79.6 % F (n = 86) 0.73
Duration of the symptoms 6.8 months ± 1.9
Median = 7 months
IQR = 13 months
Median = 60 months
IQR = 108
0.001
% (n) of patients on NSAIDs and painkillers at the
time of the scan
0.096 % (9/93) 0.194 % (21/108) 0.023
% (n) of patients on steroids at the time of US scan 0.01 (1/93) 0.05 (6/108) 0.055
Mean dose 10 mg oral prednisolone 120 mg DepoMedrone i.m.
(given 5 ± 1 week ago).
Number of days since given steroids to the time
of US scan
One patient on oral prednisolone
at the time of the scan
Mean = 19.3 ± 15.73 days
Median = 19
IQR = 21.25
N/A
hsCRP (mean ± SE) 6.92 ± 1.4 5.57 ± 0.76 0.38
Median and IQR Median = 2.7
IQR = 5.65
Median = 2.9
IQR = 5.95
0.58
ESR (mean ± SE) 17.2 ± 16.3 20.6 ± 18.8 0.62
Median and IQR Median = 12
IQR = 18
Median = 14
IQR = 22.75
0.76
% patients who had the blood tests taken within
2 weeks from the time of the US scan
98 % (92/93) 84.4 % (92/109) 0.009
% RF positive 25.8 % (24/93) 67.6 % (73/108) 0.007
% ACPA positive 24.7 % (22/89) 83 % (90/108) 0.001
Number of joints with SH grade 1 (median and IQR) Median = 1.5
IQR = 2.25
Median = 2
IQR = 4.5
0.54
Number of joints with SH grade 2 (median and IQR) Median = 0
IQR = 3
Median = 1
IQR = 3
0.025
Number of joints with SH grade 3 (median and IQR) Median = 0
IQR = 0
Median = 2
IQR = 4.25
0.013
Number of joints with PD (median and IQR) Median = 0
IQR = 1
Median = 0
IQR = 2.25
0.03
Number of joints with osteophytes (median and IQR) Median = 1
IQR = 5.25
Median = 1
IQR = 4
0.23
Number of joints with erosions (median and IQR) Median = 0
IQR = 4.5
Median = 2
IQR = 8.75
0.004
% (n) patients with PD 55.9 % (52/93) 41.6 % (45/108) 0.56
TJC (mean ± SD) 8.81 ± 9.07
Median = 5.5
9.54 ± 8.9
Median = 6
0.57
SJC (mean ± SD) 2.66 ± 5.18
Median = 1
3.73 ± 4.74
Median = 2
0.12
GVAS (mean ± SD) 61.7 ± 25.7 (n = 75) 50.7 ± 28.9 (n = 105) 0.009
Pain VAS (mean ± SD) 59.9 ± 26.6 (n = 48) 53.3 ± 31.02 (n = 60) 0.24
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Table 2 Comparison between RA patients with different levels of disease activity
Disease activity RA (n = 11)
DAS-28 <2.6
RA (n = 9)
DAS-28 = 2.6–3.2
RA (n = 39)
DAS-28 = 3.2–5.1
RA (n = 28)
DAS-28 >5.1
ANOVA/
chi-squared test
Mean age ± SD 47.08 ± 19.64 46.33 ± 12.59 58.17 ± 16.07 57.36 ± 15.69 0.051
Sex (% female) 0.67 0.56 0.65 0.70 0.885
Duration of the symptoms 7.92 6.71 11.44 8.31 0.300
hsCRP (mean ± SE) 1.56 ± 0.58 3.63 ± 2.13 5.49 ± 1.04 7.63 ± 1.73 0.127
Median and IQR 0.8 (0, 2.08) 0.9 (0, 3.2) 3.2 (1.1, 7.92) 4.4 (1.8, 11.1)
ESR (mean ± SE) 7.5 ± 1.38 9.78 ± 2.52 19.44 ± 2.60 30.33 ± 3.46 0.000
Median and IQR 5 (5, 9.25) 7 (5, 13) 13.5 (7, 25.25) 32 (12, 37)
% RF positive 0.5 0.67 0.58 0.55 0.881
% ACPA positive 0.5 0.56 0.42 0.55 0.690
Number of joints with SH grade 1 (median and IQR) 0 (0, 0.5) 0 (0, 0.5) 0 (0, 8.5) 0 (0, 2) 0.365
Number of joints with SH grade 2 (median and IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.836
Number of joints with SH grade 3 (median and IQR) 1 (0, 3.25) 0 (0, 3) 2 (0, 4.25) 3 (0, 5) 0.639
Number of joints with PD (median and IQR) 0.5 (0, 1) 0 (0, 1) 1 (0, 3) 1 (0, 4) 0.058
Number of joints with osteophytes (median and IQR) 0 (0, 5.75) 6 (0, 7) 3.5 (0, 8) 4 (0, 7) 0.993
Number of joints with erosions (median and IQR) 3.5 (1, 6.25) 4 (2, 4) 7 (2, 10) 5 (1, 11) 0.341
% patients with PD 0.5 0.33 0.63 0.67 0.257
TJC (mean ± SD) 1 ± 1.21 2.56 ± 1.81 6.51 ± 4.98 19.48 ± 7.78 0.000
SJC (mean ± SD) 1.75 ± 5.74 1.22 ± 1.92 4.98 ± 3.35 5.94 ± 5.09 0.002
GVAS (mean ± SD) 18.42 ± 24.74 34.44 ± 18.73 44.81 ± 25.44 74.55 ± 17.74 0.000
Pain VAS (mean ± SD) 11.42 ± 13.45 42 ± 26.12 49 ± 26.57 80 ± 19.10 0.000
Table 3 Comparison between S-IA patients with different levels of disease activity
Disease activity S-IA (n = 16)
DAS-28 <2.6
S-IA (n = 5)
DAS-28 = 2.6–3.2
S-IA (n = 35)
DAS 28 = 3.2–5.1
S-IA (n = 26)
DAS-28 >5.1
ANOVA/
chi-squared test
Mean age ± SD 46.41 ± 12.86 47 ± 8.75 52.4 ± 15.81 53.04 ± 17.16 0.466
Sex (% female) 0.41 0.4 0.51 0.73 0.146
Duration of the symptoms 2.37 1.5 2.11 3.98 ± 4.73 0.152
hsCRP (mean ± SE) 1.69 ± 0.383 2.86 ± 1.88 4.5 ± 1.11 15.48 ± 4.43 0.004
Median and IQR 1.3 (0.6, 2.6) 0 (0, 5) 2.3 (0.9, 4.9) 6.8 (3.55, 13.83)
ESR (mean ± SE) 7.53 ± 1.22 11.6 ± 5.64 14.2 ± 1.58 31.44 ± 4.61 0.000
Median and IQR 5 (4, 11) 6 (6, 8) 11 (7, 22) 25 (19, 35)
% RF positive 0.24 0 0.34 0.19 0.293
% ACPA positive 0.12 0.2 0.03 0.19 0.199
Number of joints with SH grade 1 (median and IQR) 0 (0, 0) 0 (0, 1) 0 (0, 2) 0 (0, 2) 0.929
Number of joints with SH grade 2 (median and IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.632
Number of joints with SH grade 3 (median and IQR) 0 (0, 0) 0 (0, 4) 0 (0, 3) 2.5 (0, 5.75) 0.023
Number of joints with PD (median and IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 1 (0, 3) 0.000
Number of joints with osteophytes (median and IQR) 2 (0, 6) 3 (2, 5) 3 (1.5, 7) 4 (1, 6.75) 0.695
Number of joints with erosions (median and IQR) 0 (0, 0) 0 (0, 1) 0 (0, 0.5) 0 (0, 2) 0.096
% patients with PD 0.06 0 0.2 0.54 0.001
TJC (mean ± SD) 0.29 ± 0.59 1.8 ± 0.837 7.37 ± 6.10 18.19 ± 8.43 0.000
SJC (mean ± SD) 0.24 ± 0.75 0 2.28 ± 4.76 5.38 ± 6.82 0.006
GVAS (mean ± SD) 24.41 ± 22.35 55 ± 29.15 64 ± 19.73 73.46 ± 17.42 0.000
Pain VAS (mean ± SD) 36.43 ± 32.75 55 ± 25.17 62.22 ± 21.57 71.87 ± 23.15 0.023
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S-IA group, DAS-28 scores above 5.1 correlated significantly
with the PD score (p = 0.048).
The binominal model analysis evaluated the impact of sev-
eral variables on the risk of having active joint inflammation
assessed by the presence of PD. The most negative values
suggested a lower risk for positive PD signal in correlation
with a certain parameter. Table 5 summarises the marginal
effects of different variables on the number of joints with PD
at the US examination in S-IA, RA patients, and patients with
other arthropathies (labelled as non S-IA and non-RA). For
instance, the average PD scores of S-IA patients increased by
0.004856 units in our prediction model as a consequence of
having a hsCRP level above rather than below 5 mg/l.
Similarly, the average PD score of a patient diagnosed with
RA and treated with tocilizumab decreased by 1.81 units as
compared to an RA patient who is not treated with tocilizumab
Table 4 Comparison between RA and S-IA patients in clinical remission, with low, moderate or high disease activity based on the DAS-28 cutoffs
Disease activity RA vs. S-IA
(patients with
DAS-28 <2.6)
(p value)
RA vs. S-IA
(patients with
DAS-28 = 2.6–3.2)
(p value)
RA vs. S-IA
(patients with
DAS-28 = 3.2–5.1)
RA vs. S-IA
(patients with
DAS-28 >5.1)
(p value)
Mean age 0.67 (0.912) −0.67 V (0.92) 5.77 (0.102) 4.32 (0.317)
Sex (% female) 0.254 (0.329) 0.156 (0.000) 0.156 (0.000) –0.03 (0.999)
Duration of the symptoms 5.549 (0.004) 5.21 (0.168) 9.33 (0.00) 4.32 (0.02)
CRP –0.13 (0.847) 0.773 (0.814) 0.98 (0.53) –7.85 (0.078)
ESR –0.029 (0.98) –1.822 (0.738) 5.24 (0.13) –1.107 (0.845)
RF positive 0.265 (0.28) 0.67 (0.064) 0.234 (0.054) 0.353 (0.013)
ACPA positive 0.382 (0.065) 0.356 (0.469) 0.395 (0.000) 0.353 (0.013)
Number of joints with SH grade 1 –0.09 (0.90) 1.578 (0.618) 2.34 (0.02) 1.26 (0.267)
Number of joints with SH grade 2 0.82 (0.268) 1.11 (0.478) 0.773 (0.125) 0.52 (0.238)
Number of joints with SH grade 3 0.941 (0.313) 0.09 (0.944) 1.08 (0.104) –0.456 (0.628)
Number of joints with PD 0.608 (0.005) 0.33 (0.169) 1.92 (0.01) 0.682 (0.516)
Number of joints with osteophytes 0.686 (0.733) 1.47 (0.445) 0.226 (0.826) –0.446 (0.734)
Number of joints with erosions 4.63 (0.003) 3.49 (0.047) 5.96 (0.000) 5.43 (0.000)
Number of patients with PD 0.44 (0.02) 0.33 (0.437) 0.43 (0.00) 0.128 (0.46)
TJC 0.706 (0.046) 0.756 (0.401) –0.86 (0.475) 1.29 (0.544)
SJC 1.515 (0.290) 1.22 (0.189) 1.01 (0.252) 0.555 (0.72)
GVAS –6.00 (0.502) –20.56 (0.132) –19.19 (0.000) 1.08 (0.815)
Pain VAS –25 (0.09) –13.00 (0.476) –13.22 (0.08) 8.125 (0.2707)
Table 5 Marginal effects of different variables on the number of joints with PD signal in patients with other arthropathies vs. S-IA vs. RA
RA status (n = 108) 0 0 1
Suspicion of IA (S-IA)
status (n = 92)
0 1 0
RF 2.76 (2.32, 3.21) 0.11 (–0.25, 0.46) –0.09 (–0.23, 0.06)
CCP –0.75 (–1.07, –0.42) 0.01061559 (–0.35, 0.37) 0.65 (0.50, 0.80)
MTX – – 0.01 (–0.12, 0.13)
Etanercept – – 0.01 (–0.12, 0.13)
Rituximab – – 0.62 (0.45, 0.79)
Tocilizumab – – –1.81 (–1.90, –1.72)
Adalimumab – – 0.79 (0.58, 1.01)
hsCRP (>5 mg/l) 0.0278 (0.0277, 0.0279) 0.004856 (0.004850, 0.004862) 0.0546 (0.0544, 0.0547)
ESR 0.01551 (0.01548, 0.01555) 0.01880 (0.01871, 0.01889) 0.007728 (0.007725, 0.007731)
TJC –0.00915 (–0.00917, –0.00914) 0.02020 (0.02010, 0.02030) –0.0018359 (–0.0018360,–0.0018357)
SJC 0.100 (0.099, 0.102) 0.086 (0.0841, 0.0879) 0.214 (0.212, 0.216)
GVAS 0.004594 (0.004590, 0.004597) –0.01021 (–0.01024,–0.01019) –0.005323 (–0.005324,–0.005321)
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(in the context of similar clinical picture and laboratory re-
sults). The most striking finding was that RA patients treated
with tocilizumab tended had a lower PD score on US exami-
nation than patients treated with other biologics or DMARDs,
despite similar clinical and laboratory findings (Table 5). The
presence of RF increased slightly the risk of positive PD score
only in patients with S-IA, and ACPA was associated with
higher risk of active disease in patients with established RA,
but had less influence on the S-IA group. Out of all three
clinical outcomes, TJC, SJC and GVAS, only the SJC corre-
lated with an increased PD score and only in patients with RA.
The effect of different variables on the risk for a higher PD
score was close to a zero value in the case of treatment with
MTX and etanercept. For example, our prediction model sug-
gested that in this group, the RA patients treated with MTX or
etanercept monotherapy had a similar risk of having active
joint inflammation on US. In this particular case, all the out-
come measures taken into consideration in the prediction
model are more relevant than being treated with MTX rather
than etanercept.
We also attempted a cluster analysis of patients with similar
DAS-28 scores using the following variables: age at scan;
duration of symptoms; CRP; ESR; SH grades 1, 2 and 3;
PD; presence of osteophytes; erosions; TJC; and SJC and
GVAS. Although there was no obvious clustering of patients
based on their diagnosis, the analysis revealed five big clusters
with a large jump in the levels of two consecutive nodes
(Fig. 1). One large cluster, including a significant proportion
of S-IA patients with DAS-28 >5.1 exhibited the smallest
amount of dissimilarity, suggesting that further analysis of
larger patient groups might help identify which parameters
are best to predict patients’ tendency to cluster in a certain
disease group. Figure 1 represents the dendogram.
Discussion
The results of our comparative analysis between the two
groups of patients reflected their selection: patients with RA
with no obvious clinical signs of active disease, but possible
subclinical synovitis, and patients with S-IA, who did not
fulfil the clinical and laboratory criteria for diagnosis of an
inflammatory arthropathy and were referred for an US scan.
As expected, the number of joints with active inflammation
and clinical swelling was low. Patients with established RA
had longer disease duration and more obvious chronic inflam-
matory changes (defined as SH and tendon inflammatory
changes). Chronic joint changes characteristic for RA are
known to pose clinical difficulty in assessing for the presence
of active inflammation. As frequently encountered in clinical
practice, patients with chronic conditions probably have better
coping strategies, and this can account for the reported differ-
ence in the GVAS assessment between the two groups, despite
similar pain scores.
A large proportion of our study patients with positive PD
signal in at least one of their hand joints was diagnosed with a
form of IA following the US scan (91.4 %, 43/47), which reiter-
ates the role of US examination in the early diagnosis of IA.
Also, our study showed that about one in two patients with
inflammatory joint pains has active arthritis based on US exam-
ination, even if they have not been previously diagnosed with
any joint disease. In addition, the DAS-28 score underestimated
Fig. 1 Dendogram showing the clustering of the patients with high disease activity score (DAS-28 >5.1) 336 × 204 mm (96 × 96 DPI)
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the presence of active inflammation in 50 % patients with RA
classified as being in clinical remission; also these RA patients
had more active disease, more erosions and joint tenderness that
subjects with S-IA included in the same disease activity group.
The binominal regression analysis model found that certain
parameters can have different impacts on the PD signal risk
prediction. It is difficult to appreciate the magnitude of the effect
of different parameters taken into consideration in this prediction
model because of the limited number of patients included in our
study. Tocilizumab is considered one of the most potent inhibi-
tors of synovial inflammation and was expected to be associated
with the lower risk for PD signal, even in the context of joint
pains. The weak impact of SJC and TJC on the PD presence is a
common finding of our prediction model and previous US stud-
ies. Our study also emphasised the limited role of the inflamma-
tory markers in predicting joint inflammation, as we found that
almost half of our RA patients with hsCRP below 5 mg/l had at
least one joint with positive PD signal.
This is the first study to propose a statistical prediction
model integrating clinical, laboratory and US parameters
aiming to predict which characteristics are associated with
an increased risk of having active joint inflammation at the
US examination in two different groups of patients. The role
of US scans in early detection of RA is well established [15],
and the probability of developing clinically apparent arthritis
in the context of positive PD signal was estimated at 94 %
[16]. The main diagnosis difficulties arise when a patient does
not fulfil criteria for a diagnosis of IA, and the availability of
US scans is limited. Despite the effort to establish guidelines
for early diagnosis of RA integrating US data [16], there are
no algorithms to help with the exclusion of IA in the context of
inflammatory hand pains. Ideally, all patients with inflamma-
tory hand pain should have an US examination to exclude
joint inflammation. The US examination was proven effective
in altering treatment decision and had increased sensitivity
compared to clinical examination [17].
Our real-life observational study confirmed that there were
differences between patients with established RA and patients
referred with suspicion of IA, in terms of parameters associ-
ated with the presence of PD in their joints and patients’ char-
acteristics. As the patients were referred to have a scan be-
cause of the difficulty to appreciate if their joints had active
inflammation or not, rather than being screened for US abnor-
malities in the context of arthritis, the two groups of patients
are not representative for the general group of patients with IA
and established RA.
It is interesting to note that the presence of SJ in patients
with suspicion of IA did not correlate with the presence of PD
at the US examination and that DAS-28 score is not able to
discriminate between RA patients with more or less active
joint inflammation on US.
It is recognised that patients with established RA have
chronic inflammatory changes, and the presence of swelling
is not always indicative of presence of active inflammation,
whereas patients with no previous diagnosis of arthritis might
get swellings if their joints become inflamed. However, pre-
vious studies found a disparity between the clinical assess-
ment of joint swelling and tenderness and the presence of
PD signal in patients with established RA [18]. In our study,
the presence of PD did not correlate with the erosion scores in
RA patients, probably because the two phenomena are tem-
porarily distinct. Previous studies have been focused on pa-
tients with early RA, establishing the importance of US for
early diagnosis [15], disease progression assessment [19] and
prediction of risk to develop arthritis [3, 20]. The emphasis of
our prediction model is rather on finding parameters that sug-
gest the need for organising an US examination in certain
categories of patients at risk, rather than establishing the pa-
tients’ risk of developing IA based on prospective serial US
examinations, as the majority of studies in the literature.
Our study has some important limitations: the number
of patients was too small for enabling definite conclusions
in relation to the risk prediction model and no practical
validation of this model was pursued as this was beyond
the scope of this study. This prediction risk model, if
validated, will ensure patient access to US scans based
on the stratification of their risk of having sub-clinical
joint inflammation to minimise the risk of under-
diagnosing active RA in the context of limited NHS clin-
ical resources. The US score used included only hand
joints as the patients referred to our US clinics had hand
joint inflammatory pains. We do not suggest the extrapo-
lation of our study findings for other joint areas or for
other inflammatory arthropathies. The distal interphalange-
al joints were not examined on purpose, as they are not
included in the RA OMERACT scores.
The performance of this prediction model improves with
the expansion of the database and also by taking into consid-
eration ‘missing US outcomes’. To address this, we plan to
collect data in parallel from two RA patient groups (who had
and had not a recent US scan) to optimise our model ability to
predict sub-clinical inflammation in the absence of recorded
US outcomes. A pilot study is also planned for the external
validation of our risk model, in which we will compare the
predicted model outcomes with the US data to assess our
model performance.
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